MELCAYA - Novel Health Care Strategies for Melanoma in Children, Adolescents, and Young Adults - Work Package 3 (WP3)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 30
SponsorUniversity of Florence

About this trial

The aim of this study is to investigate a type of skin cancer, also known as melanoma, in children, adolescents, and young adults, who will be referred to as CAYA patients in this project. The need for this study arises because this disease, in CAYA patients, is still poorly understood due to its rarity in individuals under 30 years old. This often leads to difficulties in assessing its severity and, consequently, in deciding on the necessary treatments to ensure the patient\'s recovery. The goal of this study is to examine melanoma in CAYA patients in order to gather the information needed to provide better diagnoses for affected patients and, as a result, select appropriate treatments to fight the disease and promote the patient\'s full recovery. Additionally, the data collected will be used to create a Pan-European online platform that will allow doctors across the European Union to consult the obtained data and collaborate on particularly complex melanoma cases, always with the aim of ensuring the patient\'s full recovery in the shortest possible time.

Eligibility criteria

Qualifiers

adolescent and childhood patients (< 20 years) or young adults (< 30 years)

histologically confirmed diagnosis of melanoma or intermediate/ambiguous melanocytic neoplasm (i.e., melanocytomas, SAMPUS, IAMPUS and MELTUMP according to WHO classification)

Disqualifiers

adult patients (> 30 years of age)

patients without histologically confirmed diagnosis of melanoma or intermediate/ambiguous melanocytic neoplasm

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

100 Participants
are grouped into 1 trial group

Sponsors and collaborators

University of Florence

Lead sponsor

Tubingen University Hospital

Collaborator

Maria Sklodowska-Curie National Research Institute of Oncology

Collaborator

Fondazione IRCCS ISTITUTO NAZIONALE TUMORI

Collaborator

Hospital Clinic of Barcelona

Collaborator

Istanbul University

Collaborator

University Of Perugia

Collaborator

German Cancer Research Center

Collaborator